Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aspira Women’s Health Inc. is a U.S.-based biotechnology and diagnostics company focused on the early detection and risk assessment of gynecologic cancers, primarily ovarian cancer. The company operates within the women’s health diagnostics and clinical laboratory testing industries, offering blood-based biomarker tests intended to assist physicians in assessing the likelihood of malignancy in women presenting with ovarian adnexal masses.
The company’s primary revenue is generated from proprietary diagnostic tests, including OVA1, OVA1Plus, and Overa, which are designed to support clinical decision-making prior to surgical intervention. Aspira Women’s Health Inc. primarily serves hospitals, physician groups, and gynecologic oncologists in the United States. The company was originally founded in 1993 as Vermillion, Inc. and later rebranded to its current name in 2021 to reflect a strategic focus on women’s health and broader diagnostic innovation.
Business Operations
Aspira Women’s Health Inc. operates as a single-reportable segment focused on diagnostic testing services, with revenues derived from test utilization reimbursed through a mix of commercial payers, Medicare, and direct billing arrangements. The company conducts its testing through its wholly owned clinical laboratory subsidiary, Aspira Labs, which performs high-complexity testing under CLIA certification.
Operations are primarily domestic, with laboratory and administrative activities centered in the United States. The company controls proprietary biomarker algorithms, clinical data, and testing methodologies that underpin its diagnostic offerings. There are no publicly disclosed material joint ventures; however, the company maintains payer relationships and distribution agreements to expand test adoption across healthcare systems.
Strategic Position & Investments
Strategically, Aspira Women’s Health Inc. is focused on expanding adoption of its ovarian cancer risk assessment tests while advancing next-generation diagnostics that leverage multi-marker analysis and artificial intelligence-driven analytics. Growth initiatives have included investments in clinical validation studies, payer coverage expansion, and enhancements to test accuracy and workflow efficiency.
The company has also signaled intent to broaden its diagnostic pipeline beyond ovarian cancer into other gynecologic and women’s health indications, though timelines and commercialization details remain limited in public disclosures. No major acquisitions have been completed in recent years; investment activity has primarily centered on internal R&D, intellectual property development, and commercialization infrastructure.
Geographic Footprint
Aspira Women’s Health Inc. is headquartered in the United States and generates substantially all of its revenue domestically. Its diagnostic tests are marketed and utilized primarily within U.S. healthcare systems, with payer coverage tied to U.S. reimbursement frameworks.
While the company does not currently report material international operations, its technologies are not geographically constrained, and international expansion has been identified in public communications as a potential long-term opportunity. At present, operational influence and market presence remain concentrated in North America.
Leadership & Governance
Aspira Women’s Health Inc. is led by an executive team with experience in diagnostics, life sciences, and healthcare commercialization. The leadership team emphasizes clinical evidence generation, payer alignment, and disciplined capital allocation as core elements of its strategic vision.
Key executives include:
- Michael J. Daly – President and Chief Executive Officer
- Gary S. Kramel – Chief Financial Officer
- Jeffrey A. Pfeffer – Chief Operating Officer
- Thomas P. Slavin – Chief Medical Officer
The company is governed by a board of directors responsible for oversight of strategy, risk management, and regulatory compliance. Leadership and governance information is based on the most recent publicly available company filings; where discrepancies exist across sources, data is inconclusive based on available public sources.